QuickView for TFS-II;jsessionid=FD9D07EA4FEA2E9D62FC365AA7DE59D3;jsessionid=9A293F9B4FD554D3CFAA1B9898B171E8;jsessionid=C8B5755C1AB667BEC9CC28337B057DA7;jsessionid=9A6DB3B64EC4691E87DB5822539F917C;jsessionid=021395EE77A032A88963306DAA958A91;jsessionid=68FDDE5196880815EAAA444DD79BCE1F;jsessionid=B58AACD5F750DB7CB9D03E66D21C2F87;jsessionid=4D25631C106D3C1324E5D23EC84DF91D;jsessionid=DFE0AC97E35BDA10DC704FD604347D96;jsessionid=D536BF1AA04DDC8CE6E526CCAB914971;jsessionid=74F1F4346759EA520B852BC8909A9B81;jsessionid=87F656B24C2FDBC3FE10EEC470EA1BB4 (gene)

1. Thymic stroma and TFII-I: towards new targeted therapies.
2. Proteomic analysis of SRF associated transcription complexes identified TFII-I as modulator of SRF f…
3. Structural basis for evolutionarily conserved interactions between TFIIS and Paf1C.
4. The TFIIS N-terminal domain (TND): a transcription assembly module at the interface of order and dis…
5. Astragaloside IV attenuates sunitinib-associated cardiotoxicity by inhibiting COUP-TFII.

There were no clinical trials for TFS-II;jsessionid=FD9D07EA4FEA2E9D62FC365AA7DE59D3;jsessionid=9A293F9B4FD554D3CFAA1B9898B171E8;jsessionid=C8B5755C1AB667BEC9CC28337B057DA7;jsessionid=9A6DB3B64EC4691E87DB5822539F917C;jsessionid=021395EE77A032A88963306DAA958A91;jsessionid=68FDDE5196880815EAAA444DD79BCE1F;jsessionid=B58AACD5F750DB7CB9D03E66D21C2F87;jsessionid=4D25631C106D3C1324E5D23EC84DF91D;jsessionid=DFE0AC97E35BDA10DC704FD604347D96;jsessionid=D536BF1AA04DDC8CE6E526CCAB914971;jsessionid=74F1F4346759EA520B852BC8909A9B81;jsessionid=87F656B24C2FDBC3FE10EEC470EA1BB4